Sino Biopharmaceutical Limited
1177
Kedudukan dalam Saham
#1751
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Harga Saham
$0.69080164
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$12.30B
Perubahan (1 hari)
2.86%
Perubahan (1 tahun)
-27.45%
Negara
HK
Perdagangan Sino Biopharmaceutical Limited (1177)
Kategori
Healthcare
Pendapatan untuk Sino Biopharmaceutical Limited (1177)
Pendapatan pada Jun 2026 TTM: $1.21B
Menurut laporan kewangan terkini Sino Biopharmaceutical Limited, pendapatan semasa syarikat ialah $1.21B. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $764.26M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $756.01M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Sino Biopharmaceutical Limited dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $1.21B | 66.67% |
| 2024 | $723.03M | -5.40% |
| 2023 | $764.26M | 1.09% |
| 2022 | $756.01M | -74.13% |
| 2021 | $2.92B | 280.79% |
| 2020 | $767.38M | -4.30% |
| 2019 | $801.89M | -51.74% |
| 2018 | $1.66B | 157.64% |
| 2017 | $644.90M | 33.59% |
| 2016 | $482.76M | 8.71% |
| 2015 | $444.09M | 22.80% |
| 2014 | $361.64M | 31.39% |
| 2013 | $275.23M | 19.15% |
| 2012 | $231.00M | 80.70% |
| 2011 | $127.84M | -8.96% |
| 2010 | $140.42M | 36.19% |
| 2009 | $103.10M | 33.11% |
| 2008 | $77.46M | 76.36% |
| 2007 | $43.92M | 66.73% |
| 2006 | $26.34M | 81.55% |
| 2005 | $14.51M | -64.22% |
| 2004 | $40.55M | 81.70% |
| 2003 | $22.32M | 28.38% |
| 2002 | $17.38M | 15.22% |
| 2001 | $15.09M | 37.33% |
| 2000 | $10.99M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $1.35B | 12.01% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -97.81% |
US
|
